scholarly article | Q13442814 |
P356 | DOI | 10.1111/DOM.12099 |
P698 | PubMed publication ID | 23551856 |
P50 | author | Mary Ann Banerji | Q107094856 |
Ralph A. DeFronzo | Q58689309 | ||
P2093 | author name string | R R Henry | |
G A Bray | |||
S Mudaliar | |||
R E Ratner | |||
S R Smith | |||
T A Buchanan | |||
P D Reaven | |||
D Tripathy | |||
A E Kitabchi | |||
N Musi | |||
S C Clement | |||
F B Stentz | |||
D C Schwenke | |||
P2860 | cites work | Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 |
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
Simulated change in body fatness affects Hologic QDR 4500A whole body and central DXA bone measures | Q33255201 | ||
Actos Now for the prevention of diabetes (ACT NOW) study | Q33488336 | ||
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus | Q33786881 | ||
Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. | Q33937311 | ||
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach | Q34294997 | ||
Thiazolidinediones | Q34346862 | ||
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). | Q34587610 | ||
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones | Q36050852 | ||
Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes | Q36632132 | ||
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes | Q36805400 | ||
Anomalies in the measurement of changes in total-body bone mineral by dual-energy X-ray absorptiometry during weight change | Q36893317 | ||
Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial | Q36972810 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Use of thiazolidinediones and fracture risk | Q38456774 | ||
Differential recruitment and differential regulation by physiological amines of fat cell beta-1, beta-2 and beta-3 adrenergic receptors expressed in native fat cells and in transfected cell lines | Q41471172 | ||
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor | Q41755813 | ||
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes | Q42999133 | ||
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | Q43584208 | ||
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients | Q43855921 | ||
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial | Q45161685 | ||
Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. | Q45211541 | ||
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. | Q46443909 | ||
Errors in dual-energy X-ray absorptiometry of the lumbar spine owing to fat distribution and soft tissue thickness during weight change | Q47380937 | ||
Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. | Q51561183 | ||
P433 | issue | 10 | |
P304 | page(s) | 931-937 | |
P577 | publication date | 2013-05-07 | |
P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
P1476 | title | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial | |
P478 | volume | 15 |
Q93364919 | Diabetes pharmacotherapy and effects on the musculoskeletal system |
Q92025124 | Does Weight Gain Associated with Thiazolidinedione Use Negatively Affect Cardiometabolic Health? |
Q47223058 | Laparoscopic sleeve gastrectomy compared to a multidisciplinary weight loss program for obesity--effects on body composition and protein status |
Q89949425 | Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use |
Q35054970 | Minireview: nuclear receptor regulation of osteoclast and bone remodeling |
Q38441017 | Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review |
Q52570655 | Pioglitazone Therapy and Fractures: Systematic Review and Meta-Analysis. |
Q37606430 | Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance |
Q30250347 | The current role of thiazolidinediones in diabetes management |
Q38537377 | The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis |
Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
Q34315432 | Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. |
Search more.